India, Nov. 16 -- Healthcare company Johnson & Johnson (JNJ) announced on Monday that it has agreed to acquire clinical-stage biopharmaceutical company Ollin Biosciences for $2.2 billion upfront, expanding its ophthalmology pipeline.

The company said the acquisition would add OLN324, an investigational bispecific antibody being developed for retinal diseases including wet age-related macular degeneration and diabetic macular edema.

Johnson & Johnson said the deal includes potential regulatory and commercial milestone payments of up to approximately $1.13 billion.

The company also said it would enter into a separate development funding agreement with Blackstone Inc.'s (BX) Life Sciences, under which Blackstone Life Sciences will provide $...